Coastal Meds LLC, which compounds drugs as an outsourcing facility, has voluntarily recalled all of its products marketed as sterile due to visible particles in some of the drug vials for injection, the Food and Drug Administration announced Friday. Health care providers should immediately quarantine and not administer any Coastal Meds sterile drug products intended for injection, FDA said. The agency encourages health care professionals and patients to report any adverse reactions or quality problems to the MedWatch program.  

Related News Articles

Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…
Headline
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…
Headline
White House Domestic Policy Council Director Neera Tanden spoke to Annual Meeting attendees about the environment hospitals and health systems are facing and…
Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…